Article Text

Download PDFPDF

#876 Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial
  1. Jean-Marc Classe1,
  2. Pierre Meeus2,
  3. Eric Leblanc3,
  4. Romuald Wernert4,
  5. François Quenet5,
  6. Frédéric Marchal6,
  7. Gilles Houvenaeghel7,
  8. Anne-Sophie Bats8,
  9. Fabrice Lécuru8,
  10. Gwenaël Ferron9,
  11. Cécile Brigand10,
  12. Dominique Berton1,
  13. Laurence Gladieff9,
  14. Florence Joly11,
  15. Isabelle Ray Coquard2,
  16. Sylvaine Durand-Fontanier12,
  17. Emilie Brument13,
  18. Bernard Asselain14,
  19. Loïc Campion1 and
  20. Olivier Glehen15
  1. 1ICO René Gauducheau, Saint Herblain, France
  2. 2Centre Léon Bérard, Lyon, France
  3. 3Centre Oscar Lambret, Lille, France
  4. 4Centre Paul Papin, Angers, France
  5. 5ICM Val d’Aurelle, Montpellier, France
  6. 6Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France
  7. 7Institut Paoli Calmettes, Marseille, France
  8. 8HEGP, Paris, France
  9. 9Institut Claudius Regaud – IUCT Oncopole, Toulouse, France
  10. 10Institut CHU Hautepierre, Strasbourg, France
  11. 11Centre François Baclesse, Caen, France
  12. 12CHU Dupuytren, Limoges, France
  13. 13Unicancer, Paris, France
  14. 14ARCAGY-GINECO Group, Paris, France
  15. 15Hôpital Lyon Sud, Pierre Benite, France


Introduction/Background Standard treatment for patients with first platinum-sensitive relapse of epithelial ovarian cancer (EOC) is based on surgery and second-line systemic chemotherapy. Hyperthermic intra-peritoneal chemotherapy (HIPEC) is still considered an experimental treatment.

Methodology The CHIPOR international multicentre randomised phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first peritoneal sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum-based chemotherapy, followed by complete debulking cytoreductive surgery. Patients were enrolled after completing chemotherapy and intraoperatively randomly assigned to receive HIPEC (cisplatin 75 mg/m2 at 41°C for 60 min) or not. Randomisation was performed intra-operatively after complete (CC0-CC1) cytoreductive surgery. Stratification factors were centre, surgical outcome (no residual disease vs residual <0.25 cm), chemotherapy-free interval at relapse (6–12 vs 12¬–18 vs >18 months), and planned PARP inhibitor use (yes vs no). The primary endpoint was overall survival (OS). The target sample size was 404 evaluable patients, providing 80% power at 5% alpha after 268 deaths. Secondary endpoints included progression-free survival (PFS), quality of life and pain, safety, and postoperative (≤60 days after surgery) morbidity and mortality.

Results Between May 11, 2011, and May 14, 2021, 415 patients were randomised. Baseline characteristics were well balanced between treatment arms. At the data cutoff (8 January, 2023, median follow-up 6.2 years), 272 patients (65%) had died. Efficacy results (OS, PFS, time to subsequent therapy, post-operative mortality, morbidity, QoL) will be presented.

Conclusion HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery. Ongoing analyses, including patient reported outcome, BRCA status, bevacizumab exposure, and subsequent therapy, will be presented.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.